Products Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Gadobutrol (Gadavist, Gadovist, BAY86-4875) Phase 1 Completed 💤 Quiet Magnetic Resonance Imaging
Magnetic Resonance Imaging
May 1, 2007 → Apr 1, 2008
About Gadobutrol (Gadavist, Gadovist, BAY86-4875) Gadobutrol (Gadavist, Gadovist, BAY86-4875) is a phase 1 stage product being developed by Bayer for Magnetic Resonance Imaging. The current trial status is completed. This product is registered under clinical trial identifier NCT00468819. Target conditions include Magnetic Resonance Imaging.
Clinical Trials (5) NCT ID Phase Status Start Completion Indication NCT01890434 Phase 3 Completed Aug 26, 2013 Nov 10, 2016 Coronary Artery Disease NCT01104584 Phase 3 Completed May 1, 2010 Jan 1, 2012 Breast Cancer NCT01067976 Phase 3 Completed Feb 1, 2010 Jan 1, 2012 Breast Cancer NCT00623467 Phase 3 Completed Dec 1, 2007 Dec 1, 2008 Central Nervous System Diseases NCT00468819 Phase 1 Completed May 1, 2007 Apr 1, 2008 Magnetic Resonance Imaging
Product Company Stage Hype Score HRS-9231 + Gadobutrol Jiangsu Hengrui Medicine Phase 2 D1000078 + D1000082 + D1000083 + D1000085 AstraZeneca Phase 1 Gadobutrol (Gadavist/Gadovist, BAY86-4875) Bayer Pre-clinical Gadobutrol (Gadovist, BAY86-4875) + Gadopentetate Dimeglumine (Magnevist, BAY86-4882) Bayer Phase 3 Gadoquatrane (BAY1747846) Bayer Phase 3 Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A) + Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A) Bayer Phase 2 GBCAs Bayer Pre-clinical Gadobutrol (Gadovist, BAY86-4875) Bayer Phase 3 BAY1747846 Bayer Phase 1 Gadoterate (Dotarem/Clariscan) + Gadobutrol (Gadavist/Gadovist, BAY86-4875) Bayer Approved Gadoquatrane (BAY1747846) + Gadobutrol + Gadoterate meglumine + Gadoteridol Bayer Phase 3 Gadobutrol (Gadovist, BAY86-4875) Bayer Pre-clinical Gadopentetate dimeglumine (Magnevist, BAY86-6661) Bayer Phase 3 Gadoquatrane (BAY1747846) + Gadobutrol + Gadoterate meglumine + Gadoteridol Bayer Phase 3 Gadobutrol (Gadovist, BAY86-4875) Bayer Pre-clinical Gadobutrol (Gadavist, BAY86-4875) Bayer Phase 1 BAY1747846 + Matching placebo Bayer Phase 1 Gadoquatrane (BAY1747846) 0.03 mmol Gd/kg + Gadoquatrane (BAY1747846) 0.1 mmol Gd/kg + Matching placebo Bayer Phase 1 Gadobutrol (Gadavist/Gadovist, BAY86-4875) Bayer Pre-clinical Gadoxetate disodium (Eovist/Primovist, BAY86-4873) Bayer Phase 3
Other Products from Bayer